RT Journal Article
SR Electronic
T1 Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 1390
OP 1393
DO 10.1136/jnnp.2011.244574
VO 82
IS 12
A1 Sato, Yoshihiro
A1 Iwamoto, Jun
A1 Honda, Yoshiaki
YR 2011
UL http://jnnp.bmj.com/content/82/12/1390.abstract
AB Background Incidence of a fracture, particularly in the hip joint, is high in Parkinson's disease (PD), owing to the immobilisation-induced bone resorption and vitamin D deficiency with reduced bone mineral density (BMD). The authors previously demonstrated the lowered incidence of hip fractures in PD by daily administration of risedronate and vitamin D.Methods This randomised, double-blind, placebo-controlled study was conducted to determine the efficacy of 17.5 mg once-weekly risedronate in the prevention of hip fracture in women with PD. Patients were randomly assigned to 17.5 mg risedronate once a week (n=136) or a placebo (n=136) combined with daily 1000 IU of ergocalciferol. Incidence of hip fractures was compared between the two groups during the 2-year follow-up.Results Hip fractures occurred in 15 patients in the placebo group and 3 patients in the risedronate group. The RR for hip fractures in the risedronate group as compared with the placebo group was 0.20 (95% CI 0.06 to 0.66). In the risedronate group, serum calcium levels decreased during the follow-up, while the levels in the placebo group increased. BMD increased by 3.4% in the risedronate group and decreased by 3.2% in the placebo group (p<0.01).Conclusions Treatment with once-weekly risedronate and ergocalciferol prevents hip fractures in older women with PD.